As more data emerge and more investigational drugs are studied, the “undruggable” target is coming into focus. Read more
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases
Oscar Arrieta+more
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […] Read more
IMpower010: Adjuvant Atezolizumab Improved DFS in PD-L1 Expressing Stage II-IIIA NSCLC
Leah LawrenceAdjuvant atezolizumab significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with resected stage II-IIIA NSCLC, according to the results of the IMpower010 study presented […] Read more
June 15, 2021—Canada’s medical regulatory agency approved the use of selpercatinib monotherapy for treatment of patients with metastatic RET fusion–positive NSCLC. Health Canada based its conditional approval on the LIBRETTO-001 […] Read more
The identification of activating EGFR mutations and ALK and ROS1 rearrangements has ushered in an era of precision medicine for advanced NSCLC characterized by swift advances and adaptive drug development. […] Read more
Screening for the Biggest Cancer Killer: Beating Lung Cancer Through Screening Guidelines?
Denis Horgan, PhD, LLM, MSc, BCLMany of Europe’s achievements and commitments have been exemplary in the development of health-related science, technology, and regulation, and the European Union (EU) is on the brink of providing further […] Read more
Management of Breathlessness in Lung Cancer Post-Surgery: An Interview With U.S. and U.K. Nurses
Samantha Jayne Byam+more
Breathlessness or shortness of breath (SOB) can be a short-term or long-term side effect after surgery, particularly lobectomy, for patients with NSCLC. There is good evidence now to support use […] Read more
On May 28, the US Food and Drug Administration (FDA) granted accelerated approval of sotorasib for patients with KRAS G12C-mutated NSCLC who have received at least one prior line of […] Read more
Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC
Marcelo V. Negrao+more
Despite U.S. Food and Drug Administration (FDA) approvals for the addition of anti–programmed death-ligand 1 (PD-L1) therapies to a first-line combination of etoposide plus a platinum-based agent for extensive-stage small […] Read more
October 2, 2020, saw the first U.S. Food and Drug Administration approval of a drug combination for malignant pleural mesothelioma in 16 years, since the combination cisplatin and pemetrexed was […] Read more